These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25808617)

  • 1. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
    Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
    J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
    Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
    Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis.
    Chen J; Wang J; Xu B; Zhu W; Li G
    J Mol Graph Model; 2011 Sep; 30():46-53. PubMed ID: 21764342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics simulations studies and free energy analysis on inhibitors of MDM2-p53 interaction.
    Niu RJ; Zheng QC; Zhang JL; Zhang HX
    J Mol Graph Model; 2013 Nov; 46():132-9. PubMed ID: 24211465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
    Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
    Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLICation: engineering approved drugs as potential p53-MDM2 interaction inhibitors for cancer therapy.
    Patil SP
    Med Hypotheses; 2013 Dec; 81(6):1104-7. PubMed ID: 24210632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
    Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
    Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators.
    Gomez-Monterrey I; Bertamino A; Porta A; Carotenuto A; Musella S; Aquino C; Granata I; Sala M; Brancaccio D; Picone D; Ercole C; Stiuso P; Campiglia P; Grieco P; Ianelli P; Maresca B; Novellino E
    J Med Chem; 2010 Dec; 53(23):8319-29. PubMed ID: 21058726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors.
    Wurz RP; Cee VJ
    J Med Chem; 2019 Jan; 62(2):445-447. PubMed ID: 30575392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
    Gollner A; Rudolph D; Arnhof H; Bauer M; Blake SM; Boehmelt G; Cockroft XL; Dahmann G; Ettmayer P; Gerstberger T; Karolyi-Oezguer J; Kessler D; Kofink C; Ramharter J; Rinnenthal J; Savchenko A; Schnitzer R; Weinstabl H; Weyer-Czernilofsky U; Wunberg T; McConnell DB
    J Med Chem; 2016 Nov; 59(22):10147-10162. PubMed ID: 27775892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.
    Zhang L; Ren W; Wang X; Zhang J; Liu J; Zhao L; Zhang X
    Eur J Med Chem; 2017 Jan; 126():1071-1082. PubMed ID: 28027532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors.
    Wang S; Jiang Y; Wu S; Dong G; Miao Z; Zhang W; Sheng C
    Org Lett; 2016 Mar; 18(5):1028-31. PubMed ID: 26883465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
    Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
    Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
    Gicquel M; Gomez C; Garcia Alvarez MC; Pamlard O; Guérineau V; Jacquet E; Bignon J; Voituriez A; Marinetti A
    J Med Chem; 2018 Oct; 61(20):9386-9392. PubMed ID: 30221935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Synthesis of Complex Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2-p53 Inhibitors.
    Gollner A; Weinstabl H; Fuchs JE; Rudolph D; Garavel G; Hofbauer KS; Karolyi-Oezguer J; Gmaschitz G; Hela W; Kerres N; Grondal E; Werni P; Ramharter J; Broeker J; McConnell DB
    ChemMedChem; 2019 Jan; 14(1):88-93. PubMed ID: 30458062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.